Welcome to The BioHub podcast, where we interview the top minds from across the Biotech and Pharma industry.
On this episode we were joined by Kristof Vercruysse, CEO of TargED Biopharmaceuticals, an Utrecht-based biotech who're developing a novel Targeted Enzyme Delivery approach to Thrombolysis.
On this episode, we discuss the current standard of care in indications such as TTP & Acute Ischemic Stroke and why TargED's platform represents a potential paradigm-shift for patients.
The BioHub - by Avetix